Dow Up0.13% Nasdaq Down0.31%

Celldex Therapeutics, Inc. (CLDX)

-NasdaqGS

20.70 Down 0.72(3.36%) 11:29AM EDT - Nasdaq Real Time Price

Add to Portfolio
Income StatementGet Income Statement for:
View: Annual Data | Quarterly DataAll numbers in thousands
Period EndingMar 30, 2013Dec 30, 2012Sep 29, 2012Jun 29, 2012
Total Revenue 2,414   3,647   3,113   2,009  
Cost of Revenue -   -   -   -  
Gross Profit 2,414   3,647   3,113   2,009  
Operating Expenses
Research Development14,090  13,748  11,769  11,112  
Selling General and Administrative3,138  2,644  2,836  2,219  
Non Recurring2,334  3,551  3,006  1,874  
Others253  254  253  292  
Total Operating Expenses19,815  20,197  17,864  15,497  
Operating Income or Loss (17,401) (16,550) (14,751) (13,488)
Income from Continuing Operations
Total Other Income/Expenses Net379  94  105  126  
Earnings Before Interest And Taxes(17,022)(16,456)(14,646)(13,362)
Interest Expense310  351  381  411  
Income Before Tax(17,332)(16,807)(15,027)(13,773)
Income Tax Expense -   -   -   -  
Minority Interest -   -   -   -  
Net Income From Continuing Ops(17,332)(16,807)(15,027)(13,773)
Non-recurring Events
Discontinued Operations -   -   -   -  
Extraordinary Items -   -   -   -  
Effect Of Accounting Changes -   -   -   -  
Other Items -   -   -   -  
Net Income (17,332) (16,807) (15,027) (13,773)
Preferred Stock And Other Adjustments -   -   -   -  
Net Income Applicable To Common Shares (17,332) (16,807) (15,027) (13,773)

Sign Up for a Free Trial to EDGAR Online Premium!
Get the critical business and financial information you need for more than 15,000 U.S. public companies.
Sign Up Now - Learn More

Currency in USD.